The PharmaZell Group management is very pleased to inform that the Group was acquired by Bridgepoint from DPE Deutsche Private Equity and Maxburg Capital Partners for an undisclosed sum. Bridgepoint is an international asset management firm with over €20 billion of assets under management. Commenting on the transaction, PharmaZell CEO Dr. Oliver Bolzern, said: “We welcome Bridgepoint as our new shareholder. In Bridgepoint we have found a partner who understands our business and who will work with us to help us realize our ambitions for further growth.“. Carsten Kratz, Senior Partner of Bridgepoint, Frankfurt commented: “PharmaZell represents an exciting opportunity to invest in a robust platform with an experienced management team and a high-quality customer base in the growing and non-cyclical pharma market. With a strong track record of growth, the company also offers the prospect of further new products and with Bridgepoint will have the resources and reach to further develop selective acquisition opportunities.“. Guido Prehn, Managing Partner at DPE Deutsche Private Equity, added: “Since our investment into PharmaZell in early 2014, the company has generated double-digit annual growth almost doubling in size. It has been a fantastic partnership with management and we are truly happy to have found in Bridgepoint a new growth-focused home for this great company.” https://pharmazell-group.com/wp-content/uploads/2020/02/Bridgepoint-Press-Release.pdf
Bridgepoint-Press-Release
